<DOC>
	<DOCNO>NCT00493181</DOCNO>
	<brief_summary>The goal clinical research study find IL-11 ( NeumegaTM ) may increase platelet count patient Chronic myeloid leukemia ( CML ) develop low platelet count receive therapy imatinib mesylate ( Gleevec , STI571 ) , tyrosine kinase inhibitor AMN107 , dasatinib , SK1606 . Primary Objective : 1 . To determine efficacy low-dose interleukin-11 , ( IL-11 , oprelvekin , NeumegaTM ) improve thrombocytopenia associate imatinib tyrosine kinase inhibitor therapy patient CML . Secondary Objective : 1 . To determine safety low-dose IL-11 patient CML thrombocytopenia associate imatinib tyrosine kinase inhibitor</brief_summary>
	<brief_title>Interleukin 11 , Thrombocytopenia , Imatinib Chronic Myelogenous Leukemia ( CML ) Patients</brief_title>
	<detailed_description>IL-11 hormone normally produce body play role stimulate production platelet . Before start treatment study , call `` screening test '' . These test help doctor decide eligible take part study . You blood sample ( 1 teaspoon ) collect check platelet count . Women able child must negative blood pregnancy test . If find eligible take part study , receive one injection IL-11 skin ( usually arm , legs abdomen ) 3 time week . If platelet count increase , treatment continue schedule long platelet increase observe . If treatment well tolerate enough platelet improvement , dose frequency IL-11 injection may increase . If platelet count becomes high enough , treatment may stop may also restart necessary . During therapy IL-11 , additional blood sample ( 1 teaspoon ) collect measure platelet count every week platelet stable every 2 6 week receive treatment study . No test require study . While study , continue treatment imatinib mesylate tyrosine kinase inhibitor decide doctor standard care.You take response treatment unacceptable side effect . There follow-up go study . This investigational study . The Food Drug Administration ( FDA ) approve IL-11 use chemotherapy-caused low platelet count . A maximum 30 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>CML patient chronic accelerated phase receive treatment imatinib mesylate ( Gleevec ) , tyrosine kinase inhibitor AMN107 , dasatinib , SK1606 . Grade &gt; /= 3 thrombocytopenia ( platelet &lt; 50 * 10 ( 9 ) /L ) first 4 week therapy tyrosine kinase inhibitor . Thrombocytopenia must either recurrent ( i.e. , second great episode grade &gt; /= 3 thrombocytopenia ) require dose reduction tyrosine kinase inhibitor . Signed informed consent . Expected therapy imatinib continue &gt; 3 month . Known allergy E. coli . New York Heart Association ( NYHA ) class III IV . Patient known hypersensitivity Neumega component Neumega . Thrombocytopenia consider unrelated treatment imatinib . Stem cell transplantation within 60 day . History atrial arrhythmia Pregnancy Papilledema</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>oprelvekin</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Imatinib</keyword>
	<keyword>IL-11</keyword>
	<keyword>Interleukin 11</keyword>
	<keyword>Neumega</keyword>
</DOC>